Pharmacological basis for the potential role of Azithromycin and Doxycycline in management of COVID-19 | Zendy

Ahmed S. Ali | Zendy; Mai A. ASattar | Zendy; Shahid Karim | Zendy; Dina Kutbi | Zendy; Hanin Aljohani | Zendy; Duaa Bakhshwin | Zendy; Mohammed Alsieni | Zendy; Huda M. Alkreathy | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pharmacological basis for the potential role of Azithromycin and Doxycycline in management of COVID-19

Author(s) -

Ahmed S. Ali,

Mai A. ASattar,

Shahid Karim,

Dina Kutbi,

Hanin Aljohani,

Duaa Bakhshwin,

Mohammed Alsieni,

Huda M. Alkreathy

Publication year - 2021

Publication title -

arabian journal of chemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.789

H-Index - 70

eISSN - 1878-5379

pISSN - 1878-5352

DOI - 10.1016/j.arabjc.2020.102983

Subject(s) - azithromycin , doxycycline , repurposing , intensive care medicine , antibiotics , clinical trial , pneumonia , medicine , covid-19 , drug , pharmacology , infectious disease (medical specialty) , biology , microbiology and biotechnology , disease , ecology

A novel corona virus SARS-CoV-2 has led to an outbreak of the highly infectious pandemic COVID-19 complicated viral pneumonia. Patients with risk factors frequently develop secondary infections where the role of appropriate antibiotics is mandatory. However, the efforts of drug repurposing lead to recognizing the role of certain antibiotics beyond the management of infection. The current review provided the detailed antiviral, immunomodulatory effect, unique pharmacokinetic profile of two antibiotics namely azithromycin (AZ) and doxycycline (DOX). It summarizes current clinical trials and concerns regarding the safety issues of these drugs. Azithromycin (AZ) has amazing lung tissue access, wide range antibacterial efficacy, conceivable antiviral action against COVID-19. It also showed efficacy when combined with other antiviral drugs in limited clinical trials, but many clinicians raise concerns regarding cardiovascular risk in susceptible patients. DOX has a considerable role in the management of pneumonia, it has some advantages including cardiac safety, very good access to lung tissue, potential antiviral, and immunomodulation impact by several mechanisms. The pharmacological profiles of both drugs are heightening considering these medications for further studies in the management of COVID-19.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research